Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-788 versus platinum-based chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated NSCLC
jRCT2071210098Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of mobocertinib, pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Takeda. Primary endpoint: Progression-free survival. Started Jan 2020; status: active, not recruiting.
02
Drugs
mobocertinibpemetrexedcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071210098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210098.